MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for treatment of glioblastoma (GBM) has been accepted and is now open with the U.S. Food and Drug Administration (FDA).

As quoted in the press release:

MediciNova was informed by the FDA that the proposed clinical investigation of MN-166 (ibudilast) in combination with temozolomide (TMZ) for treatment of GBM may proceed.

“We are very pleased that this important regulatory step is now completed, as we can now pursue clinical development of MN-166 in GBM, a devastating type of cancer with a high recurrence rate and very poor prognosis. As we previously reported, combination treatment of MN-166 (ibudilast) and TMZ improved survival compared to TMZ-only treatment in a GBM animal model study,” commented Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc.

Click here to read the full press release.